Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia

Results of a randomized, controlled study

Gary Schiller, Stephen D Nimer, James Gajewski, Myung Lee, Winston Ho, Mary Territo, Richard Champlin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed acute myelogenous leukemia is not established. We compared the use of cytarabine 200 mg/ m*day by continuous infusion for seven days to an intermediate-dose of cytarabine, 500 mg/m- every 12 hours for 12 doses. Thirty-seven of 52 patients assigned to conventional-dose cytarabine achieved complete remission (71% and the actuarial disease-free and overall survival after achieving remission were 22 ± 16% and 31 t 19% respectively. Thirty-seven of 50 patients assigned to intermediate-dose cytarabine achieved remission (74% and the actuarial disease-free and overall survival after achieving remission were 26 ± 16% and 39 ± 18% respectively. There were no statistically significant differences in complete remission rate, actuarial leukemia-free survival or overall survival between the groups. The most significant predictor for survival was age. Actuarial two year leukemia-free survival and overall survival for patients age >60 were 8 ± 15% and 20 ± 19% respectively compared to 36 2 14% and 54 ± 15% for patients age ≤60 (P =.058 and. 01, respectively). Induction regimen did not significantly affect disease free or overall survival for patients under or over age 60. We conclude that intermediate-dose cytarabine did not substantially improve results of induction for newly diagnosed acute myeloid leukemia.

Original languageEnglish
Pages (from-to)69-77
Number of pages9
JournalLeukemia and Lymphoma
Volume11
Issue number1-2
DOIs
StatePublished - Jan 1 1993
Externally publishedYes

Fingerprint

Cytarabine
Acute Myeloid Leukemia
Survival
Disease-Free Survival
Leukemia
Induction Chemotherapy
Appointments and Schedules

Keywords

  • AML randomized controlled study
  • Cytarabine dose intensity
  • Long term survival acute leukemia

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia : Results of a randomized, controlled study. / Schiller, Gary; Nimer, Stephen D; Gajewski, James; Lee, Myung; Ho, Winston; Territo, Mary; Champlin, Richard.

In: Leukemia and Lymphoma, Vol. 11, No. 1-2, 01.01.1993, p. 69-77.

Research output: Contribution to journalArticle

Schiller, Gary ; Nimer, Stephen D ; Gajewski, James ; Lee, Myung ; Ho, Winston ; Territo, Mary ; Champlin, Richard. / Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia : Results of a randomized, controlled study. In: Leukemia and Lymphoma. 1993 ; Vol. 11, No. 1-2. pp. 69-77.
@article{82b7046bcf1c4532944427e2d247f49f,
title = "Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia: Results of a randomized, controlled study",
abstract = "The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed acute myelogenous leukemia is not established. We compared the use of cytarabine 200 mg/ m*day by continuous infusion for seven days to an intermediate-dose of cytarabine, 500 mg/m- every 12 hours for 12 doses. Thirty-seven of 52 patients assigned to conventional-dose cytarabine achieved complete remission (71{\%} and the actuarial disease-free and overall survival after achieving remission were 22 ± 16{\%} and 31 t 19{\%} respectively. Thirty-seven of 50 patients assigned to intermediate-dose cytarabine achieved remission (74{\%} and the actuarial disease-free and overall survival after achieving remission were 26 ± 16{\%} and 39 ± 18{\%} respectively. There were no statistically significant differences in complete remission rate, actuarial leukemia-free survival or overall survival between the groups. The most significant predictor for survival was age. Actuarial two year leukemia-free survival and overall survival for patients age >60 were 8 ± 15{\%} and 20 ± 19{\%} respectively compared to 36 2 14{\%} and 54 ± 15{\%} for patients age ≤60 (P =.058 and. 01, respectively). Induction regimen did not significantly affect disease free or overall survival for patients under or over age 60. We conclude that intermediate-dose cytarabine did not substantially improve results of induction for newly diagnosed acute myeloid leukemia.",
keywords = "AML randomized controlled study, Cytarabine dose intensity, Long term survival acute leukemia",
author = "Gary Schiller and Nimer, {Stephen D} and James Gajewski and Myung Lee and Winston Ho and Mary Territo and Richard Champlin",
year = "1993",
month = "1",
day = "1",
doi = "10.3109/10428199309054732",
language = "English",
volume = "11",
pages = "69--77",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1-2",

}

TY - JOUR

T1 - Effect of induction cytarabine dose intensity on long-term survival in acute myelogenous leukemia

T2 - Results of a randomized, controlled study

AU - Schiller, Gary

AU - Nimer, Stephen D

AU - Gajewski, James

AU - Lee, Myung

AU - Ho, Winston

AU - Territo, Mary

AU - Champlin, Richard

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed acute myelogenous leukemia is not established. We compared the use of cytarabine 200 mg/ m*day by continuous infusion for seven days to an intermediate-dose of cytarabine, 500 mg/m- every 12 hours for 12 doses. Thirty-seven of 52 patients assigned to conventional-dose cytarabine achieved complete remission (71% and the actuarial disease-free and overall survival after achieving remission were 22 ± 16% and 31 t 19% respectively. Thirty-seven of 50 patients assigned to intermediate-dose cytarabine achieved remission (74% and the actuarial disease-free and overall survival after achieving remission were 26 ± 16% and 39 ± 18% respectively. There were no statistically significant differences in complete remission rate, actuarial leukemia-free survival or overall survival between the groups. The most significant predictor for survival was age. Actuarial two year leukemia-free survival and overall survival for patients age >60 were 8 ± 15% and 20 ± 19% respectively compared to 36 2 14% and 54 ± 15% for patients age ≤60 (P =.058 and. 01, respectively). Induction regimen did not significantly affect disease free or overall survival for patients under or over age 60. We conclude that intermediate-dose cytarabine did not substantially improve results of induction for newly diagnosed acute myeloid leukemia.

AB - The optimal dose and schedule of cytarabine in induction chemotherapy of newly diagnosed acute myelogenous leukemia is not established. We compared the use of cytarabine 200 mg/ m*day by continuous infusion for seven days to an intermediate-dose of cytarabine, 500 mg/m- every 12 hours for 12 doses. Thirty-seven of 52 patients assigned to conventional-dose cytarabine achieved complete remission (71% and the actuarial disease-free and overall survival after achieving remission were 22 ± 16% and 31 t 19% respectively. Thirty-seven of 50 patients assigned to intermediate-dose cytarabine achieved remission (74% and the actuarial disease-free and overall survival after achieving remission were 26 ± 16% and 39 ± 18% respectively. There were no statistically significant differences in complete remission rate, actuarial leukemia-free survival or overall survival between the groups. The most significant predictor for survival was age. Actuarial two year leukemia-free survival and overall survival for patients age >60 were 8 ± 15% and 20 ± 19% respectively compared to 36 2 14% and 54 ± 15% for patients age ≤60 (P =.058 and. 01, respectively). Induction regimen did not significantly affect disease free or overall survival for patients under or over age 60. We conclude that intermediate-dose cytarabine did not substantially improve results of induction for newly diagnosed acute myeloid leukemia.

KW - AML randomized controlled study

KW - Cytarabine dose intensity

KW - Long term survival acute leukemia

UR - http://www.scopus.com/inward/record.url?scp=0027438039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027438039&partnerID=8YFLogxK

U2 - 10.3109/10428199309054732

DO - 10.3109/10428199309054732

M3 - Article

VL - 11

SP - 69

EP - 77

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1-2

ER -